Evidence map›Paper›PMID 41139018›Full record

ArticleJournal of advanced research2026

Berberine suppresses colorectal cancer progression by inducing ferroptosis-mediated energy metabolism disorders.

Qiang Sun, Kerong Tu, Qiqi Xu, Li Yan, Shangqin Yang, Jingxuan Wang, Liangliang Lv, Hongmei Liu, Lulu Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qiang SunPersonalized Drug Research and Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial Peoples Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Kerong TuPersonalized Drug Research and Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial Peoples Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Qiqi XuPersonalized Drug Research and Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial Peoples Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Li YanPersonalized Drug Research and Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial Peoples Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China; Department of Gastrointestinal Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
Shangqin YangSchool of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Jingxuan WangPersonalized Drug Research and Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial Peoples Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Liangliang LvSchool of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Hongmei LiuPersonalized Drug Research and Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial Peoples Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Lulu CaiPersonalized Drug Research and Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial Peoples Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address: cailulu@med.uestc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBerberine (BBR), the predominant isoquinoline alkaloid in Coptidis Rhizoma, exhibits remarkable anti- colorectal cancer (CRC) activity. However, whether BBR triggers CRC cell death through ferroptosis-associated disruption of energy metabolism remains to be elucidated.

objectiveTo investigate if BBR induces mitochondrial energy metabolism disorder in CRC cells by regulating the ferroptosis signaling pathway.

methodsBBR's effects on malignant phenotypes were evaluated in vitro (human cell line HCT116, murine cell line CT26 cells at 10, 20, 40 μM) and in vivo (80 mg/kg). Target engagement and mechanistic pathways were interrogated through RNA-sequence combined with convolutional neural network-based pathway prediction, corroborated by surface plasmon resonance, cellular thermal shift assay. Downstream validation mainly included quantification of Gli1, STAT3, GPX4, SLC7A11, and FTH1 expression via RT-qPCR, Western blot, immunofluorescence, and other molecular expression and functional confirmation experiments.

resultsBBR inhibited CRC cell proliferation with IC

conclusionBBR triggers ferroptosis-mediated energy metabolism disorder by inhibiting Gli1/STAT3-FNR axis. This work provides a mechanistic support for BBR anti-CRC indications, and suggests an encouraging approach for treating CRC.

Indexed as

BerberineColorectal NeoplasmsEnergy MetabolismFerroptosisAnimalsCell Line, TumorCell ProliferationDisease ProgressionHCT116 CellsHumansMiceSignal TransductionBerberineBerberineColorectal cancerFerroptosisGli1/STAT3-FNR axisMitochondrial energy metabolism

Identifiers

PMID41139018
PMCPMC13316491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.